Breast cancer in schizophrenia could be interleukin-33-mediated

doi:10.5498/wjp.v11.i11.1065

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 11

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5234)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series.

Item

Count

PDF

303

WORD

150

HTML

3240

Figures (1-2)

323

Sum=4016

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

410

Download

808

Sum=1218

Nov 19, 2021 (publication date) through Nov 26, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Psychiatry

ISSN

2220-3206

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Psychiatr. Nov 19, 2021; 11(11): 1065-1074
Published online Nov 19, 2021. doi: 10.5498/wjp.v11.i11.1065

Full Size Figure Download Figure

Figure 2 Estrogen receptor modulators and antipsychotics in interleukin-33 targeting strategies. A: Raloxifene could be tissue-specific and improve cognition. B: Tamoxifen resistance in breast carcinoma could be improved by antipsychotics targeting IL-33. IL-33: Interleukin-33.

Citation: Borovcanin MM, Vesic K. Breast cancer in schizophrenia could be interleukin-33-mediated. World J Psychiatr 2021; 11(11): 1065-1074
URL: https://www.wjgnet.com/2220-3206/full/v11/i11/1065.htm
DOI: https://dx.doi.org/10.5498/wjp.v11.i11.1065